In melanoma, preclinical evidence revealed that niclosamide inhibited melanoma cell proliferation in vitro, independent of BRAF or NRAS mutation status, inhibiting tumour growth in xenograft models by uncoupling mitochondria and increasing metabolic stress (Figarola et al., 2018). Here, BRAF is linked to melanoma.